Kovai Medical Center and Hospital Limited (KOVAI) Fair Value & Analysis
Healthcare · IN · Market cap ₹66.1B
Fair value as of: Jul 5, 2026
From 26 valuation models · updated today
Share price +12.3% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹5,023 – ₹6,685 · fair‑value band ₹2,307 – ₹6,119 · the ₹6,042 price screens above the ₹4,839 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Kovai Medical Center and Hospital Limited (KOVAI) currently trades at ₹6,042, while our model-based Fair Value estimate is ₹4,839 — implying the stock looks roughly 19.9% overvalued today. We read business quality at 58/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Kovai Medical Center and Hospital Limited generated revenue of ₹15.9B at a net margin of 15.4%. Revenue grew 15.9% year over year. It earns a return on equity of 20.3%. Net debt stands at ₹3.1B. Fundamentals as of Jul 5, 2026
Our scenario range runs from ₹2,307 (bear case) to ₹6,119 (bull case); at ₹6,042, the current price sits within that range. The share trades about 10% below its 52-week high and 21% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -26% fair-value upside — at -20%, KOVAI screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
Kovai Medical Center and Hospital Limited provides hospital services in India. The company operates in two segments, Healthcare Services and Education Services. It operates various medical facilities, which provide services related to emergency care, cardiology, oncology, gynaecology and obstetrics, neurology, nephrology, urology, and ENT, as well as orthopaedics, gastroenterology and hepatology, emergency and trauma, and pediatrics. The company also offers preventive health check-ups and wellness programs to promote early diagnosis and better health management. In addition, it operates a medical college in Coimbatore. Further, it serves out-patients, in-patients and common public. Kovai Medical Center and Hospital Limited was incorporated in 1985 and is based in Coimbatore, India.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Kovai Medical Center and Hospital Limited reported revenue of ₹15.8B in FY2025 versus ₹9.1B in FY2021, a compound +15.0%/yr. Reported net income was ₹2.4B in FY2025, compounding +23.7%/yr from FY2021.
Is KOVAI fairly valued? → Check now
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$95.75 | R$123.65 | +29% |
| Fresenius SE FSNUY | $11.27 | $8.25 | -27% |
| Q0F Q0F | 2.76 SGD | 1.28 SGD | -54% |
| 5225 5225 | 8.70 MYR | 2.61 MYR | -70% |
| IHHHF IHHHF | $1.71 | $1.26 | -26% |
| Rede D'Or São Luiz S.A RDOR3 | R$32.50 | R$46.04 | +42% |
| Tenet Healthcare Corporation THC | $164.77 | $280.85 | +70% |
| Fresenius Medical Care AG FMS | $23.39 | $45.83 | +96% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,469 | ₹2,967 | -65% |
| DaVita Inc DVAI34 | R$1,081 | R$207.69 | -81% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Kovai Medical Center and Hospital Limited (KOVAI) undervalued?
What is the fair value of KOVAI?
What is the quality score of KOVAI?
What is the revenue of Kovai Medical Center and Hospital Limited (KOVAI)?
What is the net profit margin of KOVAI?
Does Kovai Medical Center and Hospital Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.